Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer.
Beatriz E AdradaRosalind CandelariaStacy MoulderAlastair ThompsonPeng WeiGary J WhitmanVicente ValeroJennifer K LittonLumarie SantiagoMarion E ScogginsTanya W MoseleyJason B WhiteElizabeth E RavenbergWei T YangGaiane M RauchPublished in: Cancer (2021)
The TVR percentage by US evaluation after 2 cycles of NAST may be a cost-effective early imaging biomarker for a pCR to AC/taxane-based NAST.